MyFinsight
Home
Blog
About
Issuance of series d
preferred stock and...
$5,549,207
Proceeds from 2.5m
streeterville note,...
$3,000,000
Issuance of common stock,
net of fees
$172,839
Net cash provided by
investing activities
$8,029,875
Canceled cashflow
$692,171
Net change in cash
and cash...
$558,716
Canceled cashflow
$7,471,159
Principal repayments on
the 2.5m...
$450,000
Principal repayments of
financed insurance...
$242,171
Stock-based compensation
$1,312,383
Impairment of deferred
offering costs
$748,599
Amortization of debt
discounts and deferred...
$495,950
Prepaid and other
current assets
-$237,863
Accrued liabilities
$121,479
Warrants issued to
non-employees
$108,335
Amortization - right-of-use
assets, operating lease
$103,559
Depreciation
$27,791
Accounts receivable
-$4,350
Net cash used in
operating activities
-$7,426,707
Net cash used in
investing activities
-$44,452
Canceled cashflow
$3,160,309
Net loss
-$9,141,875
Acquisition of intellectual
property - intangibles
$40,898
Purchase of property and
equipment
$3,554
Capitalized software
$715,191
Deferred offering costs
$604,736
Lease liability,
operating lease
-$119,518
Inventory
$5,362
Accounts payable
-$334
Back
Back
Cash Flow
HeartSciences Inc. (HSCS)
HeartSciences Inc. (HSCS)
source: myfinsight.com